Position paper on statin therapy;Positionspapier zur statintherapie

Clinical Research in Cardiology Supplements

Volumn 2, Issue 1, 2007, Pages 8-15

  Bohm M ^a   Laufs, U ^b   Hamm, C ^b   Andresen, D ^b   Becker, H J ^b   Borggrefe, M ^b   Brachmann, J ^b   Dietz, R ^b   Ertl, G ^b   Fleck, E ^b   Gottwik, M G ^b   de Haan, F ^b   Hoffmeister, H M ^b   Heusch, G ^b   Meinertz, T ^b   Osterspey, A ^b   Silber, S ^b   Trappe, H J ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b NONE

Author keywords

Cardiovascular risk; Cholesterol; Coronary artery disease; Statins

Indexed keywords

EID: 58149337896     PISSN: 18610706     EISSN: 18610714     Source Type: Journal    
DOI: 10.1007/s11789-006-0021-1     Document Type: Article

References (29)

1. Stamler J, Wentworth D, Neaton J, for the MRFIT Research Group (1986) Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256: 2823-2828
2. Baigent C, Keech A, Kearney PM et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278
3. Böhm M, Laufs U, Hamm CW et al. (2006) Stellungnahme zu Nutzenbewertung der Statine des Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Dtsch Ärztebl 103: B1951-1952
4. Laufs U, Hamm CW, Böhm M (2006) Statintherapie bei koronarer Herzkrankheit. Dtsch Ärztebl 103: B2356-2360
5. National Cholesterol Education Program Expert Panel (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Heart, Lung, and Blood Institute, National Institutes of Health, Publication No 02-5215. 3143-3421
6. Gohlke H, Kübler W, Mathes P et al. (2003) Positionspapier zur Primärprävention kardiovaskulärer Erkrankungen. Z Kardiol 92: 522-524
7. Arzneimittelkommission der Deutschen Ärzteschaft (http://www.akdae.de) (2002) Therapieempfehlung Fettstoffwechselstörungen. Deutscher Ärzte-Verlag, Köln, S 169-189
8. Dietz R, Rauch B (2003) Leitlinie zur Diagnose und Behandlung der chronischen koronaren Herzerkrankung der Deutschen Gesellschaft für Kardiologie-Herz-und Kreislaufforschung (DGK). Z Kardiol 92: 501-521
9. de Backer G, Ambrosioni E, Borch-Johnsen K et al. (2003) European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 10: S1-S10
10. Ärztliches Zentrum für Qualität in der Medizin (2006) Nationale Versorgungs-Leitlinie "Chronische KHK". http://www.versorgungsleitlinien.de/
11. Grundy SM, Cleeman JI, Merz CN et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227-239
12. Donner-Banzhoff N, Popert U, Laufs U (2004) Lipidsenkung mit Statinen-Titration oder feste Dosis. Dtsch Ärztebl 101: 1649-1651
13. Arzneimittelkommission der deutschen Ärzteschaft (2006) Koronare Herzkrankheit. Arzneiverordnungen, 21. Aufl. Deutscher Ärzte-Verlag, Köln
14. Gibbons RJ, Abrams J, Chatterjee K et al. (2003) ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 41: 159-168
15. Mosca L, Appel LJ, Benjamin EJ et al. (2004) Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement. Arterioscler Thromb Vasc Biol 24: e29-e50
16. Schwartz GG, Olsson AG, Ezekowitz MD et al. (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285: 1711-1718
17. Cannon CP, Braunwald E, McCabe CH et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495-1504
18. de Lemos JA, Blazing MA, Wiviott SD et al. (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292: 1307-1316
19. LaRosa JC, Grundy SM, Waters DD et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 352: 1425-1435
20. Koren MJ, Hunninghake DB (2004) Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 44: 1772-1779
21. Nissen SE, Tuzcu EM, Schoenhagen P et al. (2004) Effect of intensive compared with moderate lipidlowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 291: 1071-1080
22. Pedersen TR, Faergeman O, Kastelein JJ et al. (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294: 2437-2445
23. Scandinavian Simvastatin Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
24. Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-118
25. Istvan ES, Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 292: 1160-1164
26. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343: 425-430
27. Pasternak RC, Smith SC Jr, Bairey-Merz CN et al. (2002) ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 106: 1024-1028
28. Landmesser U, Bahlmann F, Mueller M et al. Simvastatin versus ezetimibe: pleiotropic and lipidlowering effects on endothelial function in humans. Circulation 111: 2356-2363
29. Kulp W, Greiner W, Graf von der Schulenburg JM (2005) Nutzenbewertung von Arzneimitteln durch das Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWIG) am Beispiel der Statine. Perfusion 18: 316-320